Please use this identifier to cite or link to this item:
Title: An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease
Authors: Hashweh, Nader Nael
Bartochowski, Zachary
Khoury, Rita
Grossberg, George T
Affiliations: Faculty of Medicine 
Keywords: Alzheimer’s disease
Disease-modifying therapy
Methylene blue
Tau aggregation inhibitor
Issue Date: 2020
Publisher: Taylor & Francis Online
Part of: Expert Opinion on Pharmacotherapy
Volume: 21
Issue: 6
Start page: 617
End page: 627
Alzheimer's disease (AD) is a major cause of morbidity worldwide and its prevalence is expected to rise. Previous studies involving compounds that target the accumulation of amyloid β protein have been unsuccessful, renewing interest in therapies directed against intracellular deposits of tau proteins. Derived from methylene blue, hydromethylthionine is a tau aggregation inhibitor that recently emerged as a promising disease-modifying treatment for AD.
ISSN: 14656566
DOI: 10.1080/14656566.2020.1719066
Ezproxy URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Apr 20, 2024

Record view(s)

checked on Apr 22, 2024

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.